Trial Profile
A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs SB FIX (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man
- Acronyms FIXtendz
- Sponsors Sangamo Therapeutics
- 30 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 26 Feb 2021 Planned End Date changed from 1 Jan 2021 to 1 Apr 2021.
- 26 Feb 2021 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2021.